News Releases
-
Aug 31, 2017Proceeds will Fund Operations Beyond Receipt of Phase 3 Dry Eye Trial Data
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that...
-
Aug 30, 2017Presenting on Monday, September 11 at 11:40 AM ET
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced it...
-
Aug 14, 2017Research Conducted Under Material Transfer Agreement Provides Potential Large Therapeutic Market Target for RGN-352 in the U.S. and EU
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that...
-
Jul 27, 2017Last Patient, Last Visit Completed on July 20th
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that...
-
Jun 13, 2017Research Conducted Under Material Transfer Agreement Provides Potential Therapeutic Target for RGN-352
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that...
